Porcilis PCV


adjuvanted inactivated vaccine against porcine circovirus

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR). Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.

This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).

This EPAR was last updated on 06/09/2021

Authorisation details

Product details
Porcilis PCV
Agency product number
Active substance
porcine circovirus type 2 ORF2 subunit antigen
International non-proprietary name (INN) or common name
adjuvanted inactivated vaccine against porcine circovirus
Anatomical therapeutic chemical veterinary (ATCvet) codes
Publication details
Marketing-authorisation holder
Intervet International BV
Date of issue of marketing authorisation valid throughout the European Union
Contact address
Wim de Körverstraat 35
5831 AN Boxmeer
The Netherlands

Product information

15/07/2021 Porcilis PCV - EMEA/V/C/000135 - II/0014/G

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Immunologicals for suidae

Therapeutic indication

For the active immunisation of pigs to reduce the virus load in blood and lymphoid tissues and to reduce weight loss associated with porcine-circovirus-type-2 infection occurring during the fattening period.

Onset of immunity: 2 weeks

Duration of immunity: 22 weeks

Assessment history

How useful was this page?

Add your rating